Enlivex Therapeutics (ENLV)
(Delayed Data from NSDQ)
$1.03 USD
0.00 (0.00%)
Updated Sep 26, 2025 04:00 PM ET
After-Market: $1.03 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ENLV 1.03 0.00(0.00%)
Will ENLV be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ENLV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENLV
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know
New Strong Buy Stocks for October 23rd
ENLV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for ENLV
ENLV forms Narrow Range Bar on September 27
Is ENLV gaining bearish strength? 20 Day Moving Average Resistance shows up after declining 1.44%
ENLV: D. Boral Capital Maintains Buy Rating with $13 Price Target Today | ENLV Stock News
Enlivex Therapeutics Announces Annual General Meeting for November 2025
ENLV forms 20 Day Moving Average Resistance on September 23